MJ210

MJ210 is a modulator of the NF-κB and MAPK pathways with oral activity and the ability to penetrate the blood-brain barrier, and it exhibits neuroprotective activity. In vitro, 5 μM of MJ210 can increase the survival rate of SH-SY5Y cells treated with Rotenone (HY-B1756) to 81.9% and reduce the level of ROS, etc. In vivo, 5 mg/kg of MJ210 can improve the motor impairment in a rat model of Parkinson's disease. MJ210 can be used in the research of neurological diseases, such as Parkinson's disease[1].

Product Specifications

UNSPSC

12352005

Target

NF-κB; p38 MAPK; Reactive Oxygen Species (ROS)

Related Pathways

Immunology/Inflammation; MAPK/ERK Pathway; Metabolic Enzyme/Protease; NF-κB

Field of Research

Neurological Disease

Smiles

O=C(OC1=C(OC)C=C(CCC(N2CCCCC2)=O)C=C1OC)C3=NC=CC=C3

Molecular Formula

C22H26N2O5

Molecular Weight

398.45

References & Citations

[1]Gupta S, et al. Discovery of potential Leonurine-based therapeutic lead MJ210 attenuates Parkinson's disease pathogenesis via NF-κB and MAPK pathways: Mechanistic insights from in vitro and in vivo rotenone models. Eur J Med Chem. 2025 May 5;289:117471.